AMRI increases hydroxychloroquine sulfate production to meet COVID-19 demand
AMRI, the US pharmaceutical research and development and manufacturing contractor, said it has obtained an emergency authorization from the US Food and Drug Administration (FDA) to increase the production of the malaria drug hydroxychloroquine sulfate, which is identified as a potential treatment for COVID-19.
The company said it will use the production facility in Rensselaer (production of hydroxychloroquine sulfate) to cope with rising market demand for the product.
At present, AMRI has active type II dimethylformamide for the production of hydroxychloroquine sulfate, which can meet the rising demand. The FDA authorized the emergency use of hydroxychloroquine sulfate in March to treat some patients with new coronary pneumonia admitted to the hospital.
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
2026-06-19
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Pfizer's paxlovid reduces the risk of COVID-19 by 26%
-
The battle between Pfizer and Gilead over COVID-19 drugs will continue
-
1200 cases were newly prescribed by Junshi Biologic for mild to moderate disease
-
Twenty-five COVID-19 Vaccines In China Enter Stages Of Clinical Trials
-
Pfizer to Increase Production Capacity of COVID-19 Oral Drugs, Invest 120 Million US Dollars
-
Anke Bio and Afana Collaborate on mRNA Vaccines for Mutant Strains Such as COVID-19 Omicron
-
As Low as $25/session! Pfizer's COVID-19 Oral Drug Paxlovid Generic Drug Price Released
-
Survey On Corona Deaths By Country
-
COVID-19 Drug Remdesivir Approved for Infants And Young Children
-
Roche's Q1 Performance Increases by 10%, And Total Revenue for the Year May Slow Down Due to COVID-19, Biosimilar Competition
Recommend Reading
-
MENA Pharmaceutical Regulatory Updates 2026: Key Compliance Changes for Global Pharma Companies
-
FDA Clears Sanofi’s Wayrilz (rilzabrutinib) for Adult ITP; U.S. Launch in September
-
Aficamten Beats Metoprolol in Obstructive HCM, Strengthening Case Ahead of FDA Decision
-
AstraZeneca Targets Year-End Filing for Novel Hypertension Drug Baxdrostat
-
API Supplier Audits Move to the Center of Pharma Supply Resilience
-
Barium Sulfide: Properties, Uses, and Safety
-
Negative Pressure Weighs on Adipic Acid Market, Driving Prices Down
-
Supply and Demand Game: Flexible Changes in the Melamine Market in China
-
About BPC 157: Understanding Its Side Effects and Benefits
-
Nylon 6 vs Nylon 6,6: A Practical Guide to Choosing the Right Material